Natural history of meningioma development in mice reveals: A synergy of Nf2 and p16Ink4a mutations

Brain Pathology

Volumn 18, Issue 1, 2008, Pages 62-70

  Kalamarides, Michel ^a,b,c   Stemmer Rachamimov, Anat O ^d   Takahashi, Masaya ^e   Han, Zhi Yan ^a,b   Chareyre, Fabrice ^a,b   Niwa Kawakita, Michiko ^a,b   Black, Peter M ^f   Carroll, Rona S ^f   Giovannini, Marco ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c BEAUJON HOSPITAL   (France)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; NEUROFIBROMATOSIS TYPE 2 PROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE MUTATION; HOMOZYGOSITY; KNOCKOUT MOUSE; MENINGIOMA; MOUSE; MOUSE MUTANT; MUTATION RATE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NULL ALLELE; ZYGOSITY;

ANIMALS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MUTATION; NEOPLASM INVASIVENESS; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2;

EID: 38349190206     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2007.00105.x     Document Type: Article

References (29)

1. Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH (2005) Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Ann Neurol 57 : 119 127.
2. Becher OJ, Holland EC (2006) Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66 : 3355 3358, discussion 8-9.
3. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G (2001) Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159 : 661 669.
4. Giovannini M, Robanus-Maandag E, Van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G (2000) Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14 : 1617 1630.
5. Gutmann DH, Hunter-Schaedle K, Shannon KM (2006) Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest 116 : 847 852.
6. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M (2002) Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16 : 1060 1065.
7. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91 : 649 659.
8. Kawashima M, Suzuki SO, Yamashima T, Fukui M, Iwaki T (2001) Prostaglandin D synthase (beta-trace) in meningeal hemangiopericytoma. Mod Pathol 14 : 197 201.
9. Kim H, Lim JY, Kim YH, Kim H, Park SH, Lee KH, Han H, Jeun SS, Lee JH, Rha HK (2002) Inhibition of ras-mediated activator protein 1 activity and cell growth by merlin. Mol Cells 14 : 108 114.
10. Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88 : 2887.
11. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A (2001) Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413 : 83 86.
12. Lamszus K, Vahldiek F, Mautner VF, Schichor C, Tonn J, Stavrou D, Fillbrandt R, Westphal M, Kluwe L (2000) Allelic losses in neurofibromatosis type 2-associated meningiomas. J Neuropathol Exp Neurol 59 : 504 512.
13. Louis DN, Scheitauer BW, Budka H, von Deimling A, Kepes JJ (2000) Meningiomas. In : Pathology and Genetics of Tumours of the Nervous System. P Kleihues, WK Cavenee (eds), pp. 176 184. IARC Press : Lyon.
14. Perry A (2006) Meningiomas. In : Russell & Rubinstein's Pathology of Tumors of the Nervous System. RE McLendon, MK Rosenblum, DD Bigner (eds), p. 446, Hodder Arnold : London.
15. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW (2002) A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12 : 183 190.
16. Perry A, Lusis EA, Gutmann DH (2005) Meningothelial hyperplasia: a detailed clinicopathologic, immunohistochemical and genetic study of 11 cases. Brain Pathol 15 : 109 115.
17. Robanus-Maandag E, Giovannini M, Van der Valk M, Niwa-Kawakita M, Abramowski V, Antonescu C, Thomas G, Berns A (2004) Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin. Oncogene 23 : 6541 6547.
18. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP, Dumanski JP, Rouleau GA (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6 : 180 184.
19. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85 : 27 37.
20. Sherr CJ (1998) Tumor surveillance via the ARF-p53 pathway. Genes Dev 12 : 2984 2991.
21. Sherr CJ (2001) Parsing Ink4a/Arf: "pure" p16-null mice. Cell 106 : 531 534.
22. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 : 1501 1512.
23. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, Bostrom J, Loning T, Schramm J (2001) Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 55 : 149 158.
24. Spagnoli MV, Goldberg HI, Grossman RI, Bilaniuk LT, Gomori JM, Hackney DB, Zimmerman RA (1986) Intracranial meningiomas: high-field MR imaging. Radiology 161 : 369 375.
25. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M (2004) Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 64 : 3718 3724.
26. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC (2002) Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 62 : 5551 5558.
27. Ware ML, Larson DA, Sneed PK, Wara WW, McDermott MW (2004) Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma. Neurosurgery 54 : 55 63.
28. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR (2005) The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25 : 2384 2394.
29. Yamashima T, Sakuda K, Tohma Y, Yamashita J, Oda H, Irikura D, Eguchi N, Beuckmann CT, Kanaoka Y, Urade Y, Hayaishi O (1997) Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process. J Neurosci 17 : 2376 2382.